Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analysis in breast cancer cell lines after CDK4/6 inhibition

ABSTRACT: We measured changes in expression of 20,812 genes in human breast cancer cell lines after treatment with abemaciclib

ORGANISM(S): Homo sapiens

PROVIDER: GSE99060 | GEO | 2017/08/17

SECONDARY ACCESSION(S): PRJNA387164

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-seq analysis of human breast cancer cell lines treated with abemaciclib

Project description:We measured changes in gene expression after treatment of human breast cancer cell lines with abemaciclib.

2020-09-03 | GSE157383 | GEO

ATAC-seq analysis of human breast cancer cell lines treated with abemaciclib

Project description:We measured changes in chromatin accessibility after treatment of human breast cancer cell lines with abemaciclib

2020-08-31 | GSE157082 | GEO

H3K9me3 ChIP-seq analysis of human breast cancer cell lines treated with abemaciclib

Project description:We measured changes in H3K9me3 after treatment of human breast cancer cell lines with abemaciclib

2020-08-31 | GSE157097 | GEO

Enhancer connectome analysis of human breast cancer cell lines treated with abemaciclib

Project description:We measured changes in H3K27ac-marked enhancer contacts before and after treatment of human breast cancer cell lines with abemaciclib

2020-09-03 | GSE157381 | GEO

H3K27ac ChIP-seq analysis of human breast cancer cell lines treated with abemaciclib, fulvestrant

Project description:We measured changes in H3K27ac after treatment of human breast cancer cell lines with abemaciclib, fulvestrant

2020-09-01 | GSE157222 | GEO

Transcriptional reprogramming underpinning resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer cell lines

Project description:To investigate the molecular mechanisms of resistance to ER downregulator and CDK4/6 inhibitors in ER+ breast cancer, we generated two cell lines, MCF7 and T47D, resistant to fulvestrant and abemaciclib after 6-8 months of exposure to increasing doses of the drug combination We performed gene expression profiling analysis using data obtained from RNA-seq of parental MCF7 or T47D and the respective fulvestrant and abemaciclib resistant cells

2023-06-05 | GSE227102 | GEO

Transcriptomic analysis in PDX mammary carcinoma after CDK4/6 inhibition

Project description:We measured changes in expression of 20,812 human genes PDX tumors growing in mice after treatment with abemaciclib

2017-08-17 | GSE99062 | GEO

Short term (16 hour) treatment of ER+ breast cancer cell lines with low doses of CDK4/6 inhibition

Project description:Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have improved progression free survival for metastatic, estrogen receptor positive (ER+) breast cancers, but their role in the non-metastatic setting remains unclear. We sought to understand the effects of CDK4/6 inhibition (CDK4/6i) and radiation (RT) in multiple preclinical breast cancer models. Transcriptomic and proteomic analyses were used to identify significantly altered pathways after CDK4/6i. Clonogenic assays were used to quantify the RT enhancement ratio (rER). DNA damage was quantified using γH2AX staining and the neutral comet assay. DNA repair was assessed using RAD51 foci formation and non-homologous end joining (NHEJ) reporter assays. Orthotopic xenografts were used to assess the efficacy of combination therapy. Palbociclib significantly radiosensitized multiple ER+ cell lines at low nanomolar, sub IC50 concentrations (rER: 1.21 – 1.52) and led to a decrease in the surviving fraction of cells at 2 Gy (p < 0.001). Similar results were observed in ribociclib- (rER: 1.08 - 1.68) and abemaciclib-treated (rER: 1.19 - 2.05) cells. Combination treatment decreased RAD51 foci formation (p < 0.001), leading to a suppression of HR activity, but did not affect NHEJ efficiency (p > 0.05). Immortalized breast epithelial cells and cells with acquired resistance to CDK4/6i did not demonstrate radiosensitization (rER: 0.94 – 1.11) or changes in RAD51 foci. In xenograft models, concurrent palbociclib and RT led to a significant decrease in tumor growth. These studies provide preclinical rationale to test CDK4/6i + RT in women with locally-advanced ER+ breast cancer at high risk for locoregional recurrence.

2020-09-24 | GSE155570 | GEO

ChIP-seq analysis of human breast cancer cell lines treated with abemaciclib

Project description:ChIP-seq analysis of human breast cancer cell lines treated with abemaciclib

| PRJNA547761 | ENA

ATAC-seq analysis of human breast cancer cell lines treated with abemaciclib

Project description:ATAC-seq analysis of human breast cancer cell lines treated with abemaciclib

| PRJNA547771 | ENA